NCT03879746 is a Phase 3 clinical trial of Tamsulosin in Premature Ejaculation, sponsored by Assiut University.

Who is sponsoring NCT03879746?

NCT03879746 is sponsored by Assiut University.

What drugs are being tested in NCT03879746?

Interventions in NCT03879746: Tamsulosin, Paroxetine Hydrochloride, placebo.

What condition does NCT03879746 study?

NCT03879746 studies Premature Ejaculation.

Is NCT03879746 still recruiting?

NCT03879746 is currently status unknown. Last updated 14 March 2019.

Last reviewed 2019-03-14 · How we verify

NCT03879746

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Tamsulosin on Premature Ejaculation Compared With Paroxetine Hydrochloride

Status unknown Phase 3 Last updated 14 March 2019

What this trial tests

Phase 3 trial testing Tamsulosin in Premature Ejaculation in 160 participants. Status unknown.

Timeline

1 April 2019

Primary endpoint
1 April 2020

1 May 2020

Quick facts

Lead sponsor	Assiut University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	factorial
Masking	none
Primary purpose	treatment
Enrollment	160
Start date	1 April 2019
Primary completion	1 April 2020
Estimated completion	1 May 2020

Drugs / interventions tested

Tamsulosin (tamsulosin) — full drug profile →
Paroxetine Hydrochloride — full drug profile →
placebo

Conditions studied

Premature Ejaculation — all drugs for Premature Ejaculation →

Sponsor

Assiut University

Who can join

Adults 20 to 60, male only, with Premature Ejaculation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Premature Ejaculation Diagnostic Tool
Time frame: 3 months
Patients will be asked to complete the PEDT ( Premature Ejaculation Diagnostic Tool ) Cases will be scored as follow : * Score of less than or equal 8 indicate no PE . * Score of 9 and 10 indicate probable PE . * Score of more than or equal 11 indicate PE After about 12 weeks the patients will be reevaluated also by ( PEDT ) and the results will be compared with the pretreatment ones

Sponsor's own description

A study to compare the effect of tamsulosin versus the effect of paroxetine hydrochloride and the effect of combination of them on PE.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tamsulosin

Trials testing the same drug.

NCT07467343 — Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial · Phase 4 · not yet recruiting
NCT07310797 — Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion · Phase 4 · not yet recruiting
NCT06966804 — Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms · Phase 3 · recruiting
NCT06843538 — Peri-operative Tamsulosin and Impact on Voiding Trial After Same-day Urogynecology Surgery · Phase 3 · recruiting
NCT05401032 — Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH. · Phase 2 · recruiting

Other recruiting trials for Premature Ejaculation

Currently open trials in the same condition.

NCT07442396 — The Effectiveness of Exercise in the Treatment of Erectile Dysfunction and Premature Ejaculation · NA · recruiting
NCT07434271 — Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outc · Phase 2 · recruiting
NCT06570135 — Brain Activity During Sexual Behavior in Patients With Primary Premature Ejaculation a Clinical Trial · NA · recruiting
NCT06851598 — Safety and Efficacy of Botulinum Toxin-A Injection Into Ischiocavernosus Muscle for Premature Ejaculation · Phase 2, PHASE3 · active not recruiting
NCT06605469 — Ejaculatory and Orgasmic Dysfunction Registry · recruiting

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03879746 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 14 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03879746.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing